HARVARD BIOSCIENCE develops, manufactures and markets tools used in drug discovery research at pharmaceutical and biotechnology companies, universities and government laboratories.
| Revenue (Most Recent Fiscal Year) | $94.14M |
| Net Income (Most Recent Fiscal Year) | $-12.40M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 0.32 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.00 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 6.64 |
| Pre-Tax Margin (Trailing 12 Months) | -63.43% |
| Net Margin (Trailing 12 Months) | -63.51% |
| Return on Equity (Trailing 12 Months) | -4.96% |
| Return on Assets (Trailing 12 Months) | -2.24% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.81 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.40 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 1.61 |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.34 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.02 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.07 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.32 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Common Shares Outstanding | 44.21M |
| Free Float | 40.23M |
| Market Capitalization | $29.63M |
| Average Volume (Last 20 Days) | 32.87M |
| Beta (Past 60 Months) | 1.44 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 9.00% |
| Percentage Held By Institutions (Latest 13F Reports) | 80.87% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |